Mission

You probably don’t have to look far to know someone who has been diagnosed with cancer. Every second child born today will be diagnosed with the disease sometime during their lifetime and 7 million Americans will die from it this year. At Protox, our hard work and dedication is driven by the belief that behind every statistic is a life and behind every estimate, hope. Our mission is to change these statistics for the better as we focus on developing and commercializing engineered protein toxins for the treatment of cancer and other proliferative diseases.

What's New

June 2 2010
Protox Announces Positive Six Month Phase 2B BPH Results

June 1, 2010
Protox to Present Phase 2B BPH Data at the Annual Meeting of the American Urological Association

May 13, 2010
Protox Reports First Quarter 2010 Financial Results

April 29, 2010
Protox Signs $75 Million License Agreement with Kissei for Commercialization of PRX302 in Japan for BPH and Prostate Disease

 

Events

January 11, 2010 - 8:45 am ET
Protox Therapeutics Conference Call - Webcast Link

 

Stock Quote

LAST TRADE:$0.39
TRADE TIME:3:53PM EST
CHANGE:$0.00 (0.00%)
PREV CLOSE: $0.39
OPEN:$0.39
BID:$0.385
ASK:$0.39